FDAsafety guidance66% confidence
FDA TA — ANDA219207
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Zydus Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application ANDA219207. Sponsor: SHANGHAI AUCYUN PHARMACEUTICALS CO., LTD. Submission status: TA. Submission type: ORIG. Review priority: STANDARD.
Supporting Context
- Therapeutic area
- Immunology · Corticosteroid
- Sub-indication
- General
Related signal: FDA Grants AP Status for Zydus' Methylprednisolone ANDA206751